论文部分内容阅读
目的:探讨莫沙必利治疗小儿消化不良的临床效果及意义。方法:选取我院2012年1月至2013年10月收治的小儿消化不良患者64例为观察研究对象,依据诊治用药的不同分为观察组(联用莫沙必利综合治疗组)和对照组(常规治疗组)各32例,将两组治疗过程中的实施方法与治疗效果进行分析对比,指导临床诊治小儿消化不良的实践。结果:联用莫沙必利综合治疗的患儿临床治愈率达到96.87%,在症状改善、并发症等方面好于对照组,两组比较有明显差异(P<0.05),观察组有2例开始服药2天内出现轻度不良反应,继续治疗后症状逐渐消失,其余患者均无明显不良反应,治疗前后检查未见异常。结论:莫沙必利可以显着改善小儿消化不良患儿的预后,提高治疗效果,具有积极的临床价值,值得临床应用。
Objective: To investigate the clinical effect and significance of mosapride in treating children with indigestion. Methods: Sixty-four cases of pediatric dyspepsia patients admitted from January 2012 to October 2013 in our hospital were selected as the observation subjects. According to the different diagnosis and treatment drugs, the observation group (combined with mosapride combined treatment group) and the control group (Routine treatment group) of 32 cases, the two groups in the course of the implementation of the method of treatment and treatment were analyzed and compared to guide clinical diagnosis and treatment of dyspeptic children in practice. Results: The clinical cure rate of children treated with mosapride combined was 96.87%, which was better than that of the control group in improving the symptoms and complications. There were significant differences between the two groups (P <0.05) Mild adverse reactions began to occur within 2 days after taking the medication. The symptoms gradually disappeared after continued treatment, and the other patients showed no obvious adverse reactions. No abnormalities were found in the patients before and after the treatment. Conclusion: Mosapride can significantly improve the prognosis of children with dyspepsia, improve the therapeutic effect, has a positive clinical value, it is worth clinical application.